Get the Stockscreener App
5.53
2.12%
-0.12
Bolt Biotherapeutics Inc stock is traded at $5.53, with a volume of 9,259.
It is down -2.12% in the last 24 hours and down -7.83% over the past month.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
See More
Previous Close:
$5.65
Open:
$5.48
24h Volume:
9,259
Relative Volume:
0.36
Market Cap:
$10.60M
Revenue:
$7.88M
Net Income/Loss:
$-69.20M
P/E Ratio:
-3.0219
EPS:
-1.83
Net Cash Flow:
$-69.73M
1W Performance:
-12.50%
1M Performance:
-7.83%
6M Performance:
-43.57%
1Y Performance:
-62.38%
1-Day Range:
$5.30
$5.59
1-Week Range:
$5.30
$6.4899
52-Week Range:
$5.20
$14.80
Bolt Biotherapeutics Inc Stock (BOLT) Company Profile
Name
Bolt Biotherapeutics Inc
Sector
Industry
Phone
650-665-9295
Address
900 CHESAPEAKE DRIVE, REDWOOD CITY
Compare BOLT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BOLT
Bolt Biotherapeutics Inc
|
5.53 | 10.83M | 7.88M | -69.20M | -69.73M | -1.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Bolt Biotherapeutics Inc Stock (BOLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-02-21 | Initiated | Guggenheim | Buy |
| Mar-02-21 | Initiated | Morgan Stanley | Overweight |
| Mar-02-21 | Initiated | SVB Leerink | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
Bolt Biotherapeutics Inc Stock (BOLT) Latest News
Best data tools to analyze Bolt Biotherapeutics Inc. stockBuy Alert Based on RSI and Volume - Newser
Why Bolt Biotherapeutics Inc. stock attracts strong analyst attentionRapid Trade Forecast Based on Indicators - Newser
Is it the right time to buy Bolt Biotherapeutics Inc. stockPost Market Guidance With High Returns - jammulinksnews.com
Trend analysis for Bolt Biotherapeutics Inc. this weekFree Stock Screener With Smart Filters - Newser
Key metrics from Bolt Biotherapeutics Inc.’s quarterly dataReal-Time AI Sentiment and Price Forecast - Newser
Published on: 2025-08-01 00:17:17 - Newser
Using economic indicators to assess Bolt Biotherapeutics Inc. potentialBuy Signal Forecast With Short-Term Data - Newser
Heatmap analysis for Bolt Biotherapeutics Inc. and competitorsMarket Sentiment Tracker with Smart Alerts - Newser
When is Bolt Biotherapeutics Inc. stock expected to show significant growthBeginner Investor Insights That Work - jammulinksnews.com
Why is Bolt Biotherapeutics Inc. stock attracting strong analyst attentionTop Growth Ideas To Watch Now - jammulinksnews.com
Does Bolt Biotherapeutics Inc. stock perform well during market downturnsBest Dividend Tips From AI Tools - jammulinksnews.com
Will Bolt Biotherapeutics Inc. bounce back from current supportDay Trading Signals With High Precision Reviewed - metal.it
Sector ETF performance correlation with Bolt Biotherapeutics Inc.Free Stock Market Entry Timing Signals - Newser
Can technical indicators confirm Bolt Biotherapeutics Inc.’s reversalStock Portfolio Risk and Return Analysis - Newser
How Bolt Biotherapeutics Inc. stock performs during market volatilityFree Wealth Building Stock Market Ideas - Newser
Will earnings trigger a reversal in Bolt Biotherapeutics Inc.Secure Buy Strategy Based on Risk Parameters - Newser
Is Bolt Biotherapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis InsideShort Term Trading Opportunity Watch Sees Shift - metal.it
Is BOLT's Q1 2025 EPS forecast a sign of recovery? - AInvest
Heatmap Data Shows High Activity in Bolt Biotherapeutics Inc. SectorTrade Setups With Clear Risk Limits Highlighted - metal.it
What makes Bolt Biotherapeutics Inc. stock price move sharplyBull Market Summary and Recovery Outlook - Newser
What are the technical indicators suggesting about Bolt Biotherapeutics Inc.Breakout Stocks Tips That Work - jammulinksnews.com
Best data tools to analyze Bolt Biotherapeutics Inc. stock AI-Powered Stock Trend Movement Analysis - Newser
Is Bolt Biotherapeutics Inc. a growth stock or a value stockNavigate the market with precision tools - jammulinksnews.com
Will earnings trigger a reversal in Bolt Biotherapeutics Inc. Weekly Stock Market Strategy Summary - Newser
Should I hold or sell Bolt Biotherapeutics Inc. stock in 2025Achieve superior capital gains with smart trades - jammulinksnews.com
What institutional investors are buying Bolt Biotherapeutics Inc. stockRapid return acceleration - jammulinksnews.com
How strong is Bolt Biotherapeutics Inc. company’s balance sheetFree Investment Community - jammulinksnews.com
How many analysts rate Bolt Biotherapeutics Inc. as a “Buy”Build a portfolio that delivers consistent profits - jammulinksnews.com
What analysts say about Bolt Biotherapeutics Inc. stockFree Capital Efficiency Planning - PrintWeekIndia
Bolt Biotherapeutics Inc. Stock Analysis and ForecastConsistently superior profits - PrintWeekIndia
Will Bolt Biotherapeutics Inc. stock benefit from interest rate changesConsistently superior profits - jammulinksnews.com
What institutions are buying Bolt Biotherapeutics Inc. stock nowConsistent double returns - jammulinksnews.com
What drives Bolt Biotherapeutics Inc. stock priceMarket-crushing stock picks - PrintWeekIndia
Is Bolt Biotherapeutics Inc. a good long term investmentFree Advanced Stock Screener Access - Autocar Professional
Bolt Biotherapeutics Inc Stock (BOLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):